Innate Pharma Adr (IPHA)

Jan 17, 2025

Innate Pharma shares retain Buy rating on long-term strategy - Investing.com

Jan 17, 2025

Dec 09, 2024

Nebius Group N.V (NASDAQ: NBIS)’s Upward Trend Continues - Stocks Register

Dec 09, 2024

Nov 14, 2024

Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com

Nov 14, 2024

Nov 14, 2024

Earnings call: Innate Pharma focuses on advancing cancer therapies - Investing.com

Nov 14, 2024

Nov 14, 2024

Earnings call: Innate Pharma focuses on advancing cancer therapies By Investing.com - Investing.com UK

Nov 14, 2024

Sep 13, 2024

Earnings call: Innate Pharma reports progress in drug development - Investing.com India

Sep 13, 2024

Sep 12, 2024

Earnings call: Innate Pharma reports progress in oncology pipeline - Investing.com

Sep 12, 2024

Aug 06, 2024

Contrast Security Introduces Application Detection and Response (ADR) to Identify and Block Attacks and Zero Days on Applications in Production - Business Wire

Aug 06, 2024

Jun 10, 2024

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace

Jun 10, 2024

Apr 10, 2024

All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy - Yahoo Finance

Apr 10, 2024

Mar 31, 2024

symbol__ Stock Quote Price and Forecast - CNN

Mar 31, 2024

Dec 12, 2022

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Business Wire

Dec 12, 2022

Apr 29, 2022

Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities News

Apr 29, 2022

Sep 02, 2021

IPHA stock surges on upcoming presentation for AstraZeneca-partnered asset - Seeking Alpha

Sep 02, 2021

Jan 03, 2020

The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance

Jan 03, 2020